Study Overview: This is a phase 3 study to see how safe and effective a medicine called Tildrakizumab is for people with Psoriatic Arthritis, a disease causing joint pain and skin rashes. This study is called "open label," meaning everyone knows what treatment they're getting.

What to Expect: This study is for people who were part of previous studies called INSPIRE 1 and INSPIRE 2. If you join, you'll continue with the same treatment and visits. You must agree to follow study rules, attend all visits, and have regular check-ups.

Eligibility: You must understand the study, agree to the rules, and have completed a previous study without any problems. You cannot join if you're pregnant, breastfeeding, or planning to become pregnant soon. Also, women must agree to use birth control during the study.

• **Length of Study**: Participants will continue treatment from previous studies.
• **Visits Needed**: Regular visits for check-ups and assessments.
• **Risks**: Must not have any conditions that increase risk during the study.